Regenicin (OTCMKTS:RGIN) versus Vivos Therapeutics (NASDAQ:VVOS) Critical Analysis

Vivos Therapeutics (NASDAQ:VVOS) and Regenicin (OTCMKTS:RGIN) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, risk, dividends, institutional ownership, analyst recommendations, earnings and valuation.

Earnings & Valuation

This table compares Vivos Therapeutics and Regenicin”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vivos Therapeutics	$14.58 million	1.35	-$13.58 million	($5.68)	-0.59
Regenicin	N/A	N/A	-$640,000.00	N/A	N/A

Regenicin has lower revenue, but higher earnings than Vivos Therapeutics.

Volatility & Risk

Vivos Therapeutics has a beta of 7.47, indicating that its share price is 647% more volatile than the S&P 500. Comparatively, Regenicin has a beta of -18.91, indicating that its share price is 1,991% less volatile than the S&P 500.

Profitability

This table compares Vivos Therapeutics and Regenicin’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Vivos Therapeutics	-86.19%	-335.04%	-93.58%
Regenicin	N/A	N/A	N/A

Analyst Recommendations

This is a breakdown of current ratings and target prices for Vivos Therapeutics and Regenicin, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vivos Therapeutics	0	0	2	0	3.00
Regenicin	0	0	0	0	0.00

Vivos Therapeutics currently has a consensus target price of $6.30, indicating a potential upside of 88.06%. Given Vivos Therapeutics’ stronger consensus rating and higher possible upside, equities analysts clearly believe Vivos Therapeutics is more favorable than Regenicin.

Insider and Institutional Ownership

26.4% of Vivos Therapeutics shares are owned by institutional investors. Comparatively, 0.0% of Regenicin shares are owned by institutional investors. 3.0% of Vivos Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Vivos Therapeutics beats Regenicin on 7 of the 11 factors compared between the two stocks.

About Vivos Therapeutics

Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado.

About Regenicin

Regenicin, Inc. focuses on developing and commercializing a technology of tissue-engineered skin substitutes. Its product portfolio includes NovaDerm, a multi-layered tissue-engineered living skin and cultured skin substitute product for the treatment of burns; and TempaDerm to treat smaller wound areas on patients, such as ulcers. The company products are used to restore the qualities of healthy human skin for use in the treatment of burns, chronic wounds, and various plastic surgery procedures. The company was formerly known as Windstar, Inc. and changed its name to Regenicin, Inc. in July 2010. Regenicin, Inc. was incorporated in 2007 and is headquartered in Little Falls, New Jersey.